Licensing

Breaking

RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup Heart Failure 2026: Vutrisiran Data & European Pharma News Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit Ruling

NewsMay 4, 2026

BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment

BioCryst receives $70M upfront plus milestone payments up to $275M for navenibart licensing agreement with Neopharmed Gentili's Irish affiliate in Europe.

Charlotte Meyer

News by Topic

More News Topics

Press Releases

Analysis by Topic

More Analysis Topics

Whitepapers

Browse

By Region

Directory

By Region

For Suppliers

For Brands

Resources

Popular Topics

More Topics

Browse

About Us

Get in Touch

Quick Actions

Recent Searches

Popular Topics

Suggestions

BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment